[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA201791701A1 - Диспергируемые композиции - Google Patents

Диспергируемые композиции

Info

Publication number
EA201791701A1
EA201791701A1 EA201791701A EA201791701A EA201791701A1 EA 201791701 A1 EA201791701 A1 EA 201791701A1 EA 201791701 A EA201791701 A EA 201791701A EA 201791701 A EA201791701 A EA 201791701A EA 201791701 A1 EA201791701 A1 EA 201791701A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compositions
dispensable compositions
dispensable
tuberculosis
elderly
Prior art date
Application number
EA201791701A
Other languages
English (en)
Inventor
Маниш Кумар Гупта
Шрипад Васудео Маратхе
Каустубх Рамеш Тамбвекар
Шридеви Велаюдхан Наир
Original Assignee
Янссен Фармацевтика Нв
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55229712&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201791701(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Янссен Фармацевтика Нв filed Critical Янссен Фармацевтика Нв
Publication of EA201791701A1 publication Critical patent/EA201791701A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Lubricants (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение относится к диспергируемым композициям, содержащим бедаквилина фумарат в качестве активного ингредиента. Такие композиции являются применимыми в лечении туберкулеза, а присущие им свойства диспергируемости обеспечивают им применимость, в частности, среди популяции детского или пожилого возраста.
EA201791701A 2015-01-27 2016-01-26 Диспергируемые композиции EA201791701A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN264MU2015 2015-01-27
PCT/EP2016/051545 WO2016120258A1 (en) 2015-01-27 2016-01-26 Dispersible compositions

Publications (1)

Publication Number Publication Date
EA201791701A1 true EA201791701A1 (ru) 2017-11-30

Family

ID=55229712

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791701A EA201791701A1 (ru) 2015-01-27 2016-01-26 Диспергируемые композиции

Country Status (30)

Country Link
US (2) US20180000810A1 (ru)
EP (1) EP3250182B1 (ru)
JP (3) JP7291458B2 (ru)
KR (1) KR102631986B1 (ru)
CN (2) CN114129526A (ru)
AU (2) AU2016212116B2 (ru)
CA (1) CA2973301A1 (ru)
CY (1) CY1126107T1 (ru)
DK (1) DK3250182T3 (ru)
EA (1) EA201791701A1 (ru)
ES (1) ES2948805T3 (ru)
FI (1) FI3250182T3 (ru)
HK (1) HK1243644A1 (ru)
HR (1) HRP20230616T1 (ru)
HU (1) HUE062481T2 (ru)
IL (2) IL253626B2 (ru)
LT (1) LT3250182T (ru)
MA (1) MA41411B1 (ru)
MD (1) MD3250182T2 (ru)
MX (1) MX391192B (ru)
PE (1) PE20171319A1 (ru)
PH (1) PH12017501331B1 (ru)
PL (1) PL3250182T3 (ru)
PT (1) PT3250182T (ru)
RS (1) RS64308B1 (ru)
SG (1) SG11201705944TA (ru)
SI (1) SI3250182T1 (ru)
SM (1) SMT202300188T1 (ru)
UA (1) UA126891C2 (ru)
WO (1) WO2016120258A1 (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
HRP20211450T1 (hr) * 2017-07-14 2022-01-07 Janssen Pharmaceutica Nv Dugodjelujuće formulacije
EP3773731A1 (en) * 2018-04-05 2021-02-17 Cipla Limited Pharmaceutical formulations
US11291654B2 (en) * 2018-09-13 2022-04-05 Syneurx International (Taiwan) Corp. Formulations of cycloserine compounds and applications thereof
US20220023282A1 (en) * 2018-12-13 2022-01-27 Mannkind Corporation Compositions of Bedaquiline, Combinations Comprising Them, Processes for Their Preparation, Uses and Methods of Treatment Comprising Them
KR20210113628A (ko) * 2019-01-09 2021-09-16 얀센 파마슈티카 엔.브이. 비결핵성 마이코박테리아 질환의 치료에서의 조합물
WO2021257466A1 (en) * 2020-06-15 2021-12-23 The Global Alliance For Tb Drug Development, Inc. Combination antibacterial composition and method for antibacterial therapy
EP4164626A4 (en) * 2020-06-15 2024-07-03 Mylan Laboratories Ltd. Combination antibacterial composition and method for antibacterial therapy
CN111888477B (zh) * 2020-09-15 2023-03-07 北京福元医药股份有限公司 一种贝达喹啉药物制剂
KR20230107275A (ko) * 2020-11-12 2023-07-14 얀센 파마슈티카 엔.브이. 비결핵성 마이코박테리아 질환의 치료에서 베다퀼린, 에탐부톨 및 마크롤라이드의 조합물
KR102478006B1 (ko) 2020-12-03 2022-12-15 정승찬 자동차 긴급 제동장치
GB202100470D0 (en) * 2021-01-14 2021-03-03 Summit Oxford Ltd Solid tablet dosage for of ridinilazole
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
GB202211231D0 (en) 2022-08-02 2022-09-14 Glaxosmithkline Ip No 2 Ltd Novel formulation
WO2024130214A2 (en) * 2022-12-17 2024-06-20 Via Therapeutics, Llc Clofazimine mini-tablets for treatment of tuberculosis in pediatrics

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1527050B1 (en) 2002-07-25 2010-04-07 Janssen Pharmaceutica N.V. Quinoline derivatives and their use as mycobacterial inhibitors
PT1753427E (pt) 2004-05-28 2008-07-04 Janssen Pharmaceutica Nv Utilização de derivados quinolina substituídos para o tratamento de doenças micobacterianas resistentes a fármacos
EE05394B1 (et) 2004-12-24 2011-04-15 Janssen Pharmaceutica N.V. Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis
PL1888604T3 (pl) * 2005-05-25 2012-08-31 Janssen Pharmaceutica Nv Sposób wytwarzania (alfa S, beta R)-6-bromo-alfa-[2-(dimetyloamino)etylo]-2-metoksy-alfa-1-naftalenylo-beta-fenylo-3-chinolinetanolu
EE05697B1 (et) * 2005-06-08 2014-02-17 Janssen Pharmaceutica N.V. Kinoliini derivaadid kui antibakteriaalsed toimeained
BRPI0714265A2 (pt) * 2006-08-10 2013-04-16 Cipla Ltd composiÇço oral sàlida, processo para preparar uma composiÇço oral sàlida, uso de uma composiÇço e mÉtodo para tratar hiv
UA97813C2 (ru) * 2006-12-05 2012-03-26 Янссен Фармацевтика Н.В. Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола
JO3271B1 (ar) * 2006-12-06 2018-09-16 Janssen Pharmaceutica Nv مشتقات الكوينولين المضادة للجراثيم
AU2009251563A1 (en) * 2008-04-02 2009-12-03 Dr. Reddy's Laboratories Ltd. Raloxifene pharmaceutical formulations
KR101318189B1 (ko) * 2008-09-03 2013-10-16 더 존스 홉킨스 유니버시티 결핵에 대한 병용 요법
US20120207838A1 (en) * 2011-02-10 2012-08-16 Perricone Nicholas V Treatment of Psoriasis Using Oral Dosage Forms of Nitrone Spin Traps
WO2013153162A1 (en) * 2012-04-11 2013-10-17 Sandoz Ag Polymorph of rilpivirine hydrochloride
US20140075692A1 (en) * 2012-09-18 2014-03-20 Unger Marketing International, Llc. Multiuse cleaning tool handle
RU2015117921A (ru) * 2012-11-19 2017-01-10 Азанта А/С Диспергируемая таблетка

Also Published As

Publication number Publication date
AU2021204135A1 (en) 2021-07-15
JP2022176982A (ja) 2022-11-30
DK3250182T3 (da) 2023-06-26
US20220331307A1 (en) 2022-10-20
IL253626B1 (en) 2024-04-01
ES2948805T3 (es) 2023-09-19
RS64308B1 (sr) 2023-07-31
PH12017501331B1 (en) 2024-02-14
FI3250182T3 (fi) 2023-06-28
CN107205945A (zh) 2017-09-26
PE20171319A1 (es) 2017-09-07
IL253626B2 (en) 2024-08-01
US20180000810A1 (en) 2018-01-04
SMT202300188T1 (it) 2023-07-20
MX391192B (es) 2025-03-21
PT3250182T (pt) 2023-07-07
HRP20230616T1 (hr) 2023-09-29
CA2973301A1 (en) 2016-08-04
AU2016212116B2 (en) 2021-07-15
JP7291458B2 (ja) 2023-06-15
IL310920A (en) 2024-04-01
BR112017015784A2 (pt) 2018-03-27
WO2016120258A1 (en) 2016-08-04
SI3250182T1 (sl) 2023-08-31
UA126891C2 (uk) 2023-02-22
IL253626A0 (en) 2017-09-28
HUE062481T2 (hu) 2023-11-28
EP3250182A1 (en) 2017-12-06
MA41411B1 (fr) 2023-07-31
EP3250182B1 (en) 2023-04-26
CY1126107T1 (el) 2023-11-15
MX2017009681A (es) 2017-10-18
AU2021204135B2 (en) 2023-10-05
LT3250182T (lt) 2023-07-10
HK1243644A1 (zh) 2018-07-20
CN114129526A (zh) 2022-03-04
JP2021098706A (ja) 2021-07-01
PL3250182T3 (pl) 2023-07-31
KR102631986B1 (ko) 2024-01-30
PH12017501331A1 (en) 2017-12-11
MD3250182T2 (ro) 2023-09-30
MA41411A (fr) 2017-12-05
JP2018502928A (ja) 2018-02-01
KR20170106447A (ko) 2017-09-20
AU2016212116A1 (en) 2017-07-27
SG11201705944TA (en) 2017-08-30

Similar Documents

Publication Publication Date Title
EA201791701A1 (ru) Диспергируемые композиции
CY1122329T1 (el) Anti-siglec-8 αντισωματα και μeθοδοι χρhσεως αυτων
EA201990043A1 (ru) Антибактериальные соединения
EA201890204A1 (ru) Антибактериальные соединения
ZA201805792B (en) Taurine and aloe synergistic anti-irritant compositions and methods
NZ733174A (en) Quinazoline derivatives used to treat hiv
MX2016017108A (es) Composiciones y metodos para el cuidado personal.
MX385845B (es) Usos y composiciones de la flagelina
PH12015501648B1 (en) 2-aminopyrimidine derivatives for the treatment of viral infections
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
MX362155B (es) Combinaciones de alquilamidotiazoles y sustancias aromaticas.
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
CY1123366T1 (el) Παραγωγα 8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δeκανιου
MX2018008640A (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano.
NZ745457A (en) Solvent-free formulations of low-melting active substances
MX2020001632A (es) Composiciones que comprenden cepas bacterianas.
MX2020005056A (es) Emulsiones para el tratamiento tópico de infecciones dérmicas y de mucosas.
MX391757B (es) Formulaciones de ácido 1-amino-1-ciclopropanocarboxílico.
MY178960A (en) Hiv treatment formulation of atazanavir and cobicistat
MX2015001648A (es) Composiciones que comprenden derivados de espicamicina y metodos de uso de los mismos.
MX2014011218A (es) Uso de agentes tensoactivos anfotericos para la prevencion y tratamiento de biopeliculas vaginales patogenas en infecciones vaginales.
MX2020005682A (es) Extracto de helichrysum gymnocephalum para el tratamiento y/o la prevencion de dermatosis inflamatorias.
MX360040B (es) Nuevo agente antibacteriano derivado de florfenicol unido a sulfoximina y el uso del mismo en el tratamiento de infecciones bacterianas en ganado vacuno.
MX2015015850A (es) Composiciones de sabor y fragancia que contienen tiopiran-carbaldehido.
AU2014353885A8 (en) Prevention and treatment of toxicosis